Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMAfore
NCT04689828Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 14
01
Overview
A Phase 3 trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Novartis. Started Jun 2021; status: completed.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04689828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04689828.